Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.

@article{Morgan2016OutcomesOC,
  title={Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.},
  author={Jeffrey A. Morgan and Pauline H Go and Linnea Xuereb and Babbaljeet Kaur and Silvy Akrawe and Hassan W. Nemeh and Jamil F Borgi and David E. Lanfear and Celeste Williams and Gaetano Paone},
  journal={The Annals of thoracic surgery},
  year={2016},
  volume={102 4},
  pages={1266-73}
}
BACKGROUND Continuous-flow left ventricular assist devices (LVADs) have become the standard of care for patients with advanced heart failure. The goal of this study was to review our 9-year institutional experience. METHODS From March 2006 through May 2015, 231 patients underwent implantation of 240 CF LVADs, HeartMate II LVAD (Thoratec Corp., Pleasanton, CA; n = 205) or HVAD (HeartWare Inc., Framingham, MA; n = 35). Of these, 127 devices (52.9%) were implanted as bridge to transplantation… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS